Electrophysiological monitoring of epileptic patients treated with Vigabatrin;Surveillance électrophysiologique des patients épileptiques traités par Vigabatrin

Journal Francais d'Ophtalmologie

Volumn 28, Issue 6, 2005, Pages 635-641

  Rigolet, M H ^a   Baulac, M ^b   Nordmann, J P ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anti epileptic drugs; Electro oculogram; GABA; Visual field

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; ELECTROPHYSIOLOGY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; RELIABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 22044454124     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(05)81109-X     Document Type: Article

References (21)

1. Eke T, Talbot JF, Iawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ, 1997;314:180-1.
2. Harding GF. Severe persistent visual field constriction associated with vigabratin. Four possible explanation exist. BMJ, 1997;314: 180-1.
3. Blacwell N, Hayllar J, Kelly G. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. BMJ, 1997;314:1694.
4. Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defets occur with Vigabatrin. BMJ, 1998;316:233.
5. Baulac M, Nordmann JP, Lanoé, Y. Severe visual-field constricton and side-effects of GABA-mimetic agents. Lancet, 1998;352:546.
6. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Serges JP, Berendscho TT et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia, 2001;42:262-7.
7. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin. Effect of stopping the drug. Am J Ophthalmol, 2000;130:691.
8. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, Van Veelen CW. Concentric contraction of visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia, 2000;41:581-7.
9. Lanthony P. Les effets ophtalmologiques des anticonvulsivants. Réalités Ophtalmologiques, 1999;66.
10. Noussiainen I, Kalvainen R, Mayntyjarvi M. Color Vision in epilepsy patients treated with vigabatrin of carbamazepine monotherapy. Ophthalmology, 2000;107:884-8.
11. Paulus W, Schwarz G, Steinhoff BJ. The effect of carbamazepine, phenytoin and valproic acid anti-epileptic convulsive drugs on visual perception. In: Colour Vision Deficiencies, CR Cavonius ed, 1997 Kluwer Academic Publishers (Dordrecht): p. 187-191.
12. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet, 1999;354:486.
13. Giordano L, Valseriati D, Vignoli A, Morescalchi F, Ganolfo E. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor? Neurol Sci, 2000; 21:185-6.
14. Roubertie A, Bellet H, Echenne B. Vigabatrin-associated retinal cone system dysfunction. Neurology, 1998;51:1779-81.
15. Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M. Electrophysiologic evaluation of patient with peripheral visual field contraction associated with vigabarin. Arch Ophthalmol, 1998; 116:817-9.
16. Krauss GL, Johson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophtalmologic findings. Neurologie, 1998;50:614-8.
17. McDonagh J, Grierson DJ, Keating D. The wide field multifocal ERG reveals a retinal defect caused by Vigabatrin toxicicty. Br J Ophthalmol, 2001;85:119-20.
18. Harding GF, Wild JM, Robertson KA, Lawden MC, Betts TA, Barber C etal. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field contriction. Epilepsia, 2000;41:1420-31.
19. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology, 1999;52:121-5.
20. Miller NR. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants. Neurology, 2000;55:333-4.
21. Delplace MP. Indications et résultats le l'électro- oculogramme sensoriel ou EOG S: le vigabatrin (ou Sabril®). In: Exploration de la fonction visuelle: applications au domaine de l'œil normal et en pathologie. Risse JF, Ed Masson, 1999; p. 532-3.